var data={"title":"Amiodarone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amiodarone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5617?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">see &quot;Amiodarone: Drug information&quot;</a> and <a href=\"topic.htm?path=amiodarone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amiodarone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708616\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening arrhythmias (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone is intended for use only in patients with indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Potentially fatal toxicities (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone has several potentially fatal toxicities, the most important of which is pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 10% to 17% in some series of patients with ventricular arrhythmias given doses of approximately 400 mg/day, and as abnormal diffusion capacity without symptoms in a much higher percentage of patients. Pulmonary toxicity has been fatal approximately 10% of the time. Liver injury is common with amiodarone, but is usually mild and evidenced only by abnormal liver enzymes. However, overt liver disease can occur and has been fatal in a few cases. Like other antiarrhythmics, amiodarone can exacerbate the arrhythmia (eg, by making the arrhythmia less well tolerated or more difficult to reverse). This has occurred in 2% to 5% of patients in various series, and significant heart block or sinus bradycardia has been seen in 2% to 5%. In most cases, all of these events should be manageable in the proper clinical setting. Although the frequency of such proarrhythmic events does not appear greater with amiodarone than with many other agents used in this population, the effects are prolonged when they occur.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High-risk patients (tablet):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Even in patients at high risk of arrhythmic death in whom the toxicity of amiodarone is an acceptable risk, amiodarone poses major management problems that could be life-threatening in a population at risk of sudden death; therefore, make every effort to utilize alternative agents first.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The difficulty of using amiodarone effectively and safely poses a significant risk to patients. Patients with the indicated arrhythmias must be hospitalized while the loading dose of amiodarone is given, and a response generally requires at least 1 week, usually 2 weeks or more. Because absorption and elimination are variable, maintenance dose selection is difficult, and it is not unusual to require dosage decrease or discontinuation of treatment. In a retrospective survey of 192 patients with ventricular tachyarrhythmias, 84 patients required dose reduction and 18 required at least temporary discontinuation because of adverse reactions, and several series have reported 15% to 20% overall frequencies of discontinuation because of adverse reactions. The time at which a previously controlled life-threatening arrhythmia will recur after discontinuation or dose adjustment is unpredictable, ranging from weeks to months. The patient is obviously at great risk during this time and may need prolonged hospitalization. Attempts to substitute other antiarrhythmic agents when amiodarone must be stopped will be made difficult by the gradually, but unpredictably, changing amiodarone body burden. A similar problem exists when amiodarone is not effective; it still poses the risk of an interaction with whatever subsequent treatment is tried.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133629\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cordarone [DSC];</li>\n      <li>Nexterone;</li>\n      <li>Pacerone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133630\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cordarone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050961\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Class III</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431485\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supraventricular tachycardia:</b> Limited data available: Oral: Loading dose: 10 to 20 mg/kg/day in 2 divided doses for 7 to 10 days; dosage should then be reduced to 5 to 10 mg/kg/day once daily and continued for 2 to 7 months; dosing based on a study of 50 infants (&lt;9 months of age) and neonates (as young as 1 day of life); <b>Note:</b> Patients who received a higher loading dose (20 mg/kg/day) were more likely to have a prolongation of the corrected QT interval (Etheridge 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tachyarrhythmia, including junctional ectopic tachycardia (JET), paroxysmal supraventricular tachycardia (PSVT):</b> Limited data available; the following dosing is based on studies that included neonates, infants, and children.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: IV: 5 mg/kg given over 60 minutes; <b>Note:</b> Most studies used bolus infusion time of 60 minutes to avoid hypotension; may repeat initial loading dose to a maximum total initial load: 10 mg/kg; do not exceed total daily bolus of 15 mg/kg/<b>day</b> (Etheridge 2001; Figa 1994; Haas 2008; Raja 1994; Soult 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion (if needed): <b>Note:</b> Reported dosing units for regimens are variable (mcg/kg/minute and mg/kg/day); use caution to ensure appropriate dose and dosing units are used; taper infusion as soon as clinically possible and switch to oral therapy if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on <b>mcg</b>/kg/<b>minute</b>: Initial: 5 <b>mcg</b>/kg/<b>minute</b>; increase incrementally as clinically needed; usual required dose: 10 <b>mcg</b>/kg/<b>minute</b>; range: 5 to 15 <b>mcg</b>/kg/<b>minute</b> (Figa 1994; Kovacikova 2009; Lane 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on <b>mg</b>/kg/<b>day</b>: Initial: 10 <b>mg</b>/kg/<b>day</b>; increase incrementally as clinically needed; range: 10 to 20 <b>mg</b>/kg/<b>day</b> (Haas 2008; Lane 2010; Raja 1994; Soult 1995)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050953\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">see &quot;Amiodarone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perfusing tachycardias:</b> Infants, Children, and Adolescents: IV, I.O.: Loading dose: 5 mg/kg (maximum: 300 mg/dose) over 20 to 60 minutes; may repeat twice up to maximum total dose of 15 mg/kg during acute treatment (PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Shock refractory VF or pulseless VT:</b> Infants, Children, and Adolescents: IV, I.O.: 5 mg/kg (maximum: 300 mg/dose) rapid bolus; may repeat twice up to a maximum total dose of 15 mg/kg during acute treatment (PALS [de Caen 2015]; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tachyarrhythmia, including junctional ectopic tachycardia (JET), paroxysmal supraventricular tachycardia (PSVT):</b> Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Loading dose: 10 to 15 mg/kg/day in 1 to 2 divided doses/day for 4 to 14 days or until adequate control of arrhythmia or prominent adverse effects occur; dosage should then be reduced to 5 mg/kg/day given once daily for several weeks; if arrhythmia does not recur, reduce to lowest effective dosage possible; usual daily minimal dose: 2.5 mg/kg/day; maintenance doses may be given for 5 of 7 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For infants, some have suggested BSA-directed dosing: Loading dose: 600 to 800 mg/<b>1.73 m<sup>2</sup></b>/day in 1 to 2 divided doses (equivalent to 347 to 462 mg/m<sup>2</sup>/day); maintenance dose: 200 to 400 mg/<b>1.73 m<sup>2</sup></b>/day once daily (equivalent to 116 to 231 mg/m<sup>2</sup>/day) (Bucknall 1986; Coumel 1980; Coumel 1983; Paul 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Prolongation of the corrected QT interval was more likely in infants &lt;9 months of age who received higher loading doses (20 mg/kg/day vs 10 mg/kg/day in 2 divided doses) (n=50; mean age: 1 &plusmn; 1.5 months) (Etheridge 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 5 mg/kg (maximum: 300 mg/dose) given over 60 minutes; <b>Note:</b> Most studies used bolus infusion time of 60 minutes to avoid hypotension; may repeat initial loading dose to a maximum total initial load: 10 mg/kg; do not exceed total daily bolus of 15 mg/kg/<b>day</b> (Etheridge 2001; Figa 1994; Haas 2008; Raja 1994; Soult 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Dividing the 5 mg/kg loading dose into 1 mg/kg aliquots (each administered over 5 to 10 minutes) has been used; an additional 1 to 5 mg/kg loading dose was given in the same manner, if needed, after 30 minutes (Perry 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion (if needed); <b>Note:</b> Reported dosing units for regimens are variable (mcg/kg/minute and mg/kg/day); use caution to ensure appropriate dose and dosing units are used; taper infusion as soon as clinically possible and switch to oral therapy if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosing based on <b>mcg</b>/kg/<b>minute</b>: Initial: 5 <b>mcg</b>/kg/<b>minute</b>; increase incrementally as clinically needed; usual required dose: 10 <b>mcg</b>/kg/<b>minute</b>; range: 5 to 15 <b>mcg</b>/kg/<b>minute</b>; maximum daily dose: 2200 mg/<b>day</b> (Figa 1994; Kovacikova 2009; Lane 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosing based on <b>mg</b>/kg/<b>day</b>: Initial: 10 <b>mg</b>/kg/<b>day</b>; increase incrementally as clinically needed; range: 10 to 20 <b>mg</b>/kg/<b>day</b>; maximum daily dose: 2,200 mg/<b>day</b> (Lane 2010; Perry 1996; Raja 1994; Soult 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Lower loading and maintenance doses are preferable in women and all patients with low body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Ventricular arrhythmias:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Prevention of recurrent life-threatening ventricular arrhythmias (eg, VF or hemodynamically unstable VT):</b> Oral: 800 to 1,600 mg daily in 1 to 2 doses for 1 to 3 weeks, then when adequate arrhythmia control is achieved, decrease to 600 to 800 mg daily in 1 to 2 doses for 1 month; maintenance: 400 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pulseless VT or VF</b> (ACLS [Link 2015]; ACLS [Neumar 2010]); IV push, I.O.: Initial: 300 mg rapid bolus; if pulseless VT or VF continues after subsequent defibrillation attempt or recurs, administer supplemental dose of 150 mg. <b>Note:</b> In this setting, administering <b>undiluted</b> is preferred (Dager 2006; Skrifvars 2004). <i>The Handbook of Emergency Cardiovascular Care</i> (Hazinski 2015) and the ACLS guidelines do not make any specific recommendations regarding dilution of amiodarone in this setting. Experience is limited with I.O. administration of amiodarone. Maximum recommended total daily dose is 2.2 g (ACLS [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Upon return of spontaneous circulation:</i> Follow with an infusion of 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours (mean daily doses &gt;2.1 g daily have been associated with hypotension).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Stable VT:</b> IV: 150 mg over 10 minutes, then 1 mg/minute for 6 hours, followed by 0.5 mg/minute; continue this rate for at least 18 hours (total infusion duration: 24 hours) <b>or</b> until complete transition to oral (see Recommendations for conversion to oral amiodarone after IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Breakthrough stable VT:</i> 150 mg supplemental doses in 100 mL D<sub>5</sub>W or NS over 10 minutes (mean daily doses &gt;2.1 g/day have been associated with hypotension)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommendations for conversion to oral amiodarone after IV administration:</b> Conversion from IV to oral therapy has not been formally evaluated. Some experts recommend a 1 to 2 day overlap when converting from IV to oral therapy especially when treating ventricular arrhythmias. Use the following as a guide:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;1 week infusion: 800 to 1,600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 week infusion: 600 to 800 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;3 week infusion: 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommendations for conversion to intravenous amiodarone after oral administration:</b> During long-term amiodarone therapy (ie, &ge;4 months), the mean plasma-elimination half-life of the active metabolite of amiodarone in adults is 61 days. Replacement therapy may not be necessary in such patients if oral therapy is discontinued for a period &lt;2 weeks, since any changes in serum amiodarone concentrations during this period may <b>not</b> be clinically significant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: IV, Oral: No adjustment necessary; nondialyzable (parent and metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: IV, Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is probably necessary in substantial hepatic impairment; no specific guidelines available. If hepatic enzymes exceed 3 times normal or double in a patient with an elevated baseline, consider decreasing the dose or discontinuing amiodarone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133598\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nexterone: 150 mg/100 mL (100 mL); 360 mg/200 mL (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg/3 mL (3 mL); 450 mg/9 mL (9 mL); 900 mg/18 mL (18 mL); 1000 mg/500 mL in dextrose 5% (500 mL); 150 mg/100 mL in Dextrose 5% (100 mL); 450 mg/250 mL in dextrose 5% (250 mL); 750 mg/500 mL in dextrose 5% (500 mL); 900 mg/500 mL in Dextrose 5% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cordarone: 200 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pacerone: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pacerone: 200 mg [scored; contains fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pacerone: 400 mg [scored; contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 200 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133581\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26978976\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">see &quot;Amiodarone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Vials for injection contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates. Commercially-prepared premixed solutions do not contain benzyl alcohol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874279\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cordarone: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018972s053lbl.pdf#page=22&amp;token=qXOvkirrIAw0B7LLnFXqlGNeW30Y0YQaf15xxAjFKA1JjbICjyoU+yldY7ChkiGMMgFHaItybK8G6k2HitQaQAh1B7PLRR7V/pTkSfMX4rADdnC1GM1t0UXi3G/g+l6c&amp;TOPIC_ID=12587\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018972s053lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pacerone: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlbDRGHP/zX3kXo5tkdFrZrg==&amp;TOPIC_ID=12587\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050966\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer at same time in relation to meals; do not administer with grapefruit juice. In adults, may administer in divided doses with meals if GI upset occurs or if taking large daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Adjust administration rate to patient's clinical condition and urgency; give slowly to patients who have a pulse (ie, perfusing arrhythmia). With perfusing arrhythmias (eg, atrial fibrillation, stable ventricular tachycardia), do not exceed recommended IV concentrations or rates of infusion listed below (severe hepatic toxicity may occur). Slow the infusion rate if hypotension or bradycardia develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulseless VT or VF: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: Administer via rapid IV bolus; adult data in this setting suggest administration of undiluted drug may be preferred (Dager 2006; Skrifvars 2004). <b>Note:</b> PALS guidelines (Kleinman 2010) do not specify dilution of bolus dose and <i>The Handbook of Emergency Cardiovascular Care</i> (Hazinski 2015) and the ACLS guidelines do not make any specific recommendations regarding dilution of amiodarone in this setting.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: May be administered rapidly and undiluted. <b>Note:</b> <i>The Handbook of Emergency Cardiovascular Care</i> (Hazinski 2015) and the 2010 ACLS guidelines do not make any specific recommendations regarding dilution of amiodarone in this setting; however, in this setting, administering undiluted is preferred (Dager 2006; Skrifvars 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perfusing arrhythmias:</b> Information based on adult data: Injection must be diluted before IV use. Administer via central venous catheter, if possible; increased phlebitis may occur with peripheral infusions &gt;3 mg/mL in D<sub>5</sub>W; the use of a central venous catheter with concentrations &gt;2 mg/mL for infusions &gt;1 hour is recommended. An in-line filter has been recommended during administration for continuous infusions to reduce the incidence of phlebitis. Must be infused via volumetric infusion device; drop size of IV solution may be reduced and underdosage may occur if drop counter-infusion sets are used. PVC tubing is recommended for administration regardless of infusion duration. <b>Incompatible</b> with heparin; flush with saline prior to and following infusion. <b>Note:</b> IV administration at lower flow rates (potentially associated with use in pediatrics) and higher concentrations than recommended may result in leaching of plasticizers (DEHP) from intravenous tubing. DEHP may adversely affect male reproductive tract development. Alternative means of dosing and administration (1 mg/kg aliquots) may need to be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: Administer loading dose over 60 minutes; may be followed by continuous infusion (Figa 1994; Haas 2008; Raja 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: Administer loading dose over 20 to 60 minutes (PALS [Kleinman 2010]); may be followed by continuous IV infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471287\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 1.8 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133622\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store undiluted vials and premixed solutions (Nexterone) at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light during storage; protect from excessive heat. There is no need to protect solutions from light during administration. When vial contents are admixed in D5W to a final concentration of 1-6 mg/mL, amiodarone is stable for 24 hours in glass or polyolefin bottles and for 2 hours in polyvinyl chloride (PVC) bags; do not use evacuated glass containers as buffer may cause precipitation. Nexterone is available as premixed solutions. Although amiodarone adsorbs to PVC tubing, all clinical studies used PVC tubing and the recommended doses account for adsorption; in adults, PVC tubing is recommended. Discard any unused portions of premixed solutions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050965\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Management of life-threatening recurrent ventricular arrhythmias [eg, recurrent ventricular fibrillation (VF) or recurrent hemodynamically unstable ventricular tachycardia (VT)] unresponsive to other therapy or in patients intolerant to other therapy (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Initiation of management and prophylaxis of frequently recurrent VF and hemodynamically unstable VT unresponsive to other therapy; VF and VT in patients requiring amiodarone who are not able to take oral therapy (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Also has been used to treat supraventricular arrhythmias unresponsive to other therapy. Amiodarone is recommended in the PALS guidelines for SVT (unresponsive to vagal maneuvers and adenosine). It is recommended in both the PALS and ACLS guidelines for cardiac arrest with pulseless VT or VF (unresponsive to defibrillation, CPR, and vasopressor administration) and control of hemodynamically-stable monomorphic VT or wide-complex tachycardia of uncertain origin. The drug is also recommended in the ACLS guidelines for re-entry SVT (unresponsive to vagal maneuvers and adenosine); control of rapid ventricular rate due to conduction via an accessory pathway in pre-excited atrial arrhythmias; control of stable narrow-complex tachycardia; and control of polymorphic VT with a normal QT interval.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133691\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amiodarone may be confused with amantadine, aMILoride, inamrinone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cordarone may be confused with Cardura, Cordran</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Amiodarone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older as first-line therapy for atrial fibrillation (unless patient has concomitant heart failure or substantial left ventricular hypertrophy) due to increased toxicities compared to other antiarrhythmics used in atrial fibrillation (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International Issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amyben [brand name for amiodarone (Great Britain)] may be confused with Ambien [US, Argentina, Israel]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133688\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Asystole, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac arrhythmia, cardiac failure, cardiogenic shock, edema, exacerbation of cardiac arrhythmia, flushing, hypotension (more common in intravenous; refractory in rare cases), nodal arrhythmia, prolonged Q-T interval on ECG (associated with worsening arrhythmia), sinus bradycardia, sinus node dysfunction, torsades de pointes, ventricular fibrillation, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, altered sense of smell, ataxia, dizziness (more common in oral), fatigue, headache, insomnia, involuntary body movements, malaise, paresthesia, peripheral neuropathy, sleep disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin photosensitivity, solar dermatitis, Stevens-Johnson syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hyperthyroidism, hypothyroidism, phospholipidemia (pulmonary phospholipidosis; more common in oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, altered salivation, anorexia, constipation, diarrhea, dysgeusia, nausea (more common in oral), vomiting (more common in oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Blood coagulation disorder, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatic disease, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision (more common in oral), corneal deposits, dry eye syndrome, optic neuritis, photophobia, visual disturbance, visual halos around lights</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Adult respiratory distress syndrome, hypersensitivity pneumonitis, pneumonitis, pneumonitis (alveolar), pulmonary edema, pulmonary fibrosis (more common in oral), pulmonary toxicity (more common in oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute pancreatitis, acute renal failure, agranulocytosis, alopecia, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, aplastic anemia, back pain, blue-gray skin pigmentation, bronchiolitis obliterans organizing pneumonia, bronchospasm, bullous dermatitis, cardiac conduction disturbance (including bundle branch block, infra-HIS block, and antegrade conduction via an accessory pathway), cholestasis, cholestatic hepatitis, confusion, cough, delirium, demyelinating disease (polyneuropathy), disorientation, DRESS syndrome, drug-induced Parkinson disease, dyspnea, eczema, eosinophilic pneumonitis, epididymitis, epithelial keratopathy (vortex, Chan 2015), erythema multiforme, exfoliative dermatitis, fever, granulocytosis, hallucination, hemolytic anemia, hemoptysis, hepatic cirrhosis, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypoesthesia, hypotension, hypoxia, impotence, increased intracranial pressure, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum creatinine, infusion site reaction (including cellulitis, edema, erythema, extravasation possibly leading to venous/infusion site necrosis, granuloma, hypoesthesia, induration, inflammation, intravascular amiodarone deposition/mass, pain, phlebitis, pigment changes, pruritus, skin sloughing, thrombophlebitis, thrombosis, urticaria), interstitial pneumonitis, jaundice, lupus-like syndrome, malignant neoplasm of skin, malignant neoplasm of thyroid, mass (pulmonary), muscle spasm, myasthenia, myopathy, myxedema (including myxedema coma), neutropenia, optic neuropathy, pancytopenia, pleural effusion, pleurisy, pruritus, pseudotumor cerebri, pulmonary alveolar hemorrhage, pulmonary infiltrates, respiratory distress syndrome, respiratory failure, rhabdomyolysis, SIADH, sinoatrial arrest, skin carcinoma, skin granuloma, skin rash, spontaneous ecchymoses, thyroid nodule, thyrotoxicosis, toxic epidermal necrolysis, urticaria, vasculitis, ventricular premature contractions, visual field defect, wheezing, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133607\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to amiodarone, iodine, or any component of the formulation; severe sinus-node dysfunction causing marked sinus bradycardia; second- and third-degree heart block (except in patients with a functioning artificial pacemaker); bradycardia causing syncope (except in patients with a functioning artificial pacemaker); cardiogenic shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling (oral formulation):</i> Additional contraindications (not in US labeling): Evidence of hepatitis; pulmonary interstitial abnormalities; thyroid dysfunction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133585\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia/hypotension: May cause hypotension and bradycardia (infusion-rate related). Hypotension with rapid administration has been attributed to the emulsifier polysorbate 80. Commercially-prepared premixed solutions do not contain polysorbate 80 and may have a lower incidence of hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: May cause life-threatening or fatal cutaneous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN). If symptoms or signs (eg, progressive skin rash often with blisters or mucosal lesions) occur, immediately discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity:<b> [US Boxed Warning (tablet)]: Liver toxicity is common, but usually mild with evidence of only increased liver enzymes; severe liver toxicity can occur and has been fatal in a few cases.</b> Hepatic enzyme levels are frequently elevated in patients exposed to amiodarone; most cases are asymptomatic. If increases &gt;3x ULN (or &ge;2x baseline in patients with preexisting elevations), consider dose reduction or discontinuation. Monitor hepatic enzymes regularly in patients on relatively high maintenance doses. Elevated bilirubin levels have been reported have been reported in patients administered IV amiodarone. <b>Note:</b> Although the US Boxed Warning pertains to the tablet prescribing information, these effects may also be seen with intravenous administration depending on duration of use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Peripheral neuropathy has been reported rarely with chronic administration; may resolve when amiodarone is discontinued, but resolution may be slow and incomplete.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Regular ophthalmic examination (including slit lamp and fundoscopy) is recommended. May cause optic neuropathy and/or optic neuritis resulting in visual impairment (peripheral vision loss, changes in acuity) at any time during therapy; permanent blindness has occurred. If symptoms of optic neuropathy and/or optic neuritis occur, prompt ophthalmic evaluation is recommended. If diagnosis of optic neuropathy and/or optic neuritis is confirmed, reevaluate amiodarone therapy. Corneal microdeposits occur in a majority of adults and may cause visual disturbances in up to 10% of patients (blurred vision, halos); asymptomatic microdeposits may be reversible and are not generally considered a reason to discontinue treatment. Corneal refractive laser surgery is generally contraindicated in amiodarone users (from manufacturers of surgical devices).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Avoid excessive exposure to sunlight; may cause photosensitivity. During long-term treatment, a blue-gray discoloration of exposed skin may occur; risk increased in patients with fair complexion or excessive sun exposure; may be related to cumulative dose and duration of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: <b>[US Boxed Warning (tablet)]: Amiodarone can exacerbate arrhythmias, by making them more difficult to tolerate or reverse;</b> other types of arrhythmias have occurred, including significant heart block, sinus bradycardia, new ventricular fibrillation, incessant ventricular tachycardia, increased resistance to cardioversion, and polymorphic ventricular tachycardia associated with QTc prolongation (torsades de pointes [TdP]). Risk may be increased with concomitant use of other antiarrhythmic agents or drugs that prolong the QTc interval. Proarrhythmic effects may be prolonged. <b>Note:</b> Although the US Boxed Warning pertains to the tablet prescribing information, these effects may also be seen with intravenous administration depending on duration of use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: <b>[US Boxed Warning (tablet)]: Pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis and abnormal diffusion capacity without symptoms) may occur.</b> Reports of acute-onset pulmonary injury (pulmonary infiltrates and/or mass on X-ray, pulmonary alveolar hemorrhage, pleural effusion, pulmonary fibrosis, bronchospasm, wheezing, fever, dyspnea, cough, hemoptysis, hypoxia) have occurred; some cases have progressed to respiratory failure and/or death. Fatalities due to pulmonary toxicity occur in ~10% of cases; most fatalities due to sudden cardiac death occurred when amiodarone was discontinued; rule out other causes of respiratory impairment before discontinuing amiodarone in patients with life-threatening arrhythmias; use extreme caution if dose is decreased or discontinued. If hypersensitivity pneumonitis occurs, discontinue amiodarone and institute steroid therapy; if interstitial/alveolar pneumonitis occurs, institute steroid therapy and reduce amiodarone dose or preferably, discontinue. Some cases of interstitial/alveolar pneumonitis may resolve following dosage reduction and steroid therapy; rechallenge at a lower dose has not resulted in return of interstitial/alveolar pneumonitis in some patients; however, in some patients the pulmonary lesions have not been reversible. Educate patients about monitoring for symptoms (eg, nonproductive cough, dyspnea, pleuritic pain, hemoptysis, wheezing, weight loss, fever, malaise). Evaluate new respiratory symptoms; preexisting pulmonary disease does not increase risk of developing pulmonary toxicity, but if pulmonary toxicity develops then the prognosis is worse. Use of lower doses may be associated with a decreased incidence, but pulmonary toxicity has been reported in patients treated with low doses. The lowest effective dose should be used as appropriate for the acuity/severity of the arrhythmia being treated. <b>Note:</b> Although the US Boxed Warning pertains to the tablet prescribing information, these effects may also be seen with intravenous administration depending on duration of use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid effects: May cause hyper- or hypothyroidism; hyperthyroidism may result in thyrotoxicosis (including fatalities) and/or the possibility of arrhythmia breakthrough or aggravation. If any new signs of arrhythmia appear, consider the possibility of hyperthyroidism. Hypothyroidism (sometimes severe) may be primary or subsequent to resolution of preceding amiodarone-induced hyperthyroidism; myxedema (may be fatal) has been reported. If hyper- or hypothyroidism occurs, reduce dose or discontinue amiodarone. Thyroid nodules and/or thyroid cancer have also been reported. Use caution in patients with thyroid disease; thyroid function should be monitored prior to treatment and periodically thereafter, particularly in the elderly and in patients with underlying thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Appropriate use:<b> [US Boxed Warnings (tablet)]: Only indicated for patients with life-threatening arrhythmias because of risk of substantial toxicity. Alternative therapies should be tried first before using amiodarone. Patients should be hospitalized when amiodarone is initiated.</b> Currently, the 2015 ACLS guidelines recommend the consideration of IV amiodarone as the preferred antiarrhythmic for the treatment of pulseless VT/VF unresponsive to CPR, defibrillation, and vasopressor therapy (AHA [Link 2015]). In patients with non-life-threatening arrhythmias (eg, atrial fibrillation), amiodarone should be used only if the use of other antiarrhythmics has proven ineffective or are contraindicated. <b>Note:</b> Although the US Boxed Warning pertains to the tablet prescribing information, these effects may also be seen with intravenous administration depending on duration of use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac devices (eg, implanted defibrillators, pacemakers): Chronic administration of antiarrhythmic drugs may affect defibrillation or pacing thresholds. Assess when initiating amiodarone and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia, hypomagnesemia, or hypocalcemia, prior to use and throughout therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: In the setting of acute myocardial infarction, beta-blocker therapy should still be initiated even though concomitant amiodarone therapy provides beta-blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wolff-Parkinson-White (WPW) syndrome: Amiodarone should not be used in patients with WPW syndrome and preexcited atrial fibrillation/flutter since ventricular fibrillation may result (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drugs metabolized by CYP enzymes: Amiodarone is a potent inhibitor of CYP enzymes and transport proteins (including p-glycoprotein), which may lead to increased serum concentrations/toxicity of a number of medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drugs with QT prolongation potential: Particular caution must be used when a drug with QTc-prolonging potential relies on metabolism via enzymes amiodarone inhibits, since the effect of elevated concentrations may be additive with the effect of amiodarone. Carefully assess risk:benefit of coadministration of other drugs which may prolong QTc interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Warfarin: Use caution when initiating amiodarone in patients on warfarin. Cases of increased INR with or without bleeding have occurred in patients treated with warfarin; monitor INR closely after initiating amiodarone in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Use caution and close perioperative monitoring in surgical patients; may enhance myocardial depressant and conduction effects of halogenated inhalational anesthetics; adult respiratory distress syndrome (ARDS) has been reported postoperatively (fatal in rare cases). Hypotension upon discontinuation of cardiopulmonary bypass during open-heart surgery have been reported (rare); relationship to amiodarone is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Commercially-prepared premixed infusion: Contains the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency, although the clinical significance of this finding is uncertain (Luke, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: There has been limited experience in patients receiving IV amiodarone for &gt;3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Use of amiodarone post-MI was not associated with an increase in mortality in two post-MI trials. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Patients may still be at risk for amiodarone-related adverse reactions or drug interactions after the drug has been discontinued. The pharmacokinetics are complex (due to prolonged duration of action and half-life) and difficult to predict.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133676\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (major), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (moderate), CYP2C9 (moderate), CYP2D6 (weak), CYP3A4 (weak), OCT2, P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133590\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12587&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agalsidase Alfa: Amiodarone may diminish the therapeutic effect of Agalsidase Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agalsidase Beta: Amiodarone may diminish the therapeutic effect of Agalsidase Beta. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class Ia): Amiodarone may enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).  Management: Avoid whenever possible. While considered contraindicated in some places, amiodarone U.S. prescribing information suggests that use could be considered under some circumstances, with careful monitoring. Reduce quinidine or procainamide dose by one third.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Amiodarone may increase the serum concentration of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May enhance the QTc-prolonging effect of Amiodarone. Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Amiodarone may enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the bioavailability of Amiodarone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amiodarone may increase the serum concentration of Cardiac Glycosides.  Management: Reduce the dose of cardiac glycosides by 30% to 50%  or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects  of cardiac glycosides.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Amiodarone. Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for increased amiodarone concentrations/effects with cimetidine initiation/dose increase or decreased concentrations/effects with cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Amiodarone may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the adverse/toxic effect of Amiodarone. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amiodarone may increase the serum concentration of CycloSPORINE (Systemic).  Management: Monitor for increased serum concentrations and/or toxicity of cyclosporine if combined with amiodarone. A reduction in cyclosporine dosage will likely be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inhibitors): CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Amiodarone may increase the serum concentration of Dabigatran Etexilate.  Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by U.S. vs. Canadian labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C8 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C8 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May enhance the bradycardic effect of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Amiodarone may enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide.  Management: Decrease flecainide dose by 50% in the presence of amiodarone.  Monitor for adverse effects of flecainide and consider monitoring for elevated serum concentrations during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the QTc-prolonging effect of Amiodarone. Fosphenytoin may decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Fosphenytoin. Management: Seek alternatives when possible. Monitor patients receiving this combination for QT interval prolongation or changes in cardiac rhythm, and for decreased serum concentrations/effects of amiodarone and increased concentrations/effects of phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease serum concentrations of the active metabolite(s) of Amiodarone. Grapefruit Juice may increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Amiodarone may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofepramine: May enhance the arrhythmogenic effect of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May enhance the QTc-prolonging effect of Amiodarone. Lopinavir may increase the serum concentration of Amiodarone. More specifically, Lopinavir/Ritonavir may increase the serum concentration of Amiodarone. Management: If this combination cannot be avoided, monitor for increased amiodarone serum concentrations and effects as well as for evidence of QT interval prolongation.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loratadine: Amiodarone may increase the serum concentration of Loratadine.  Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Amiodarone may increase the serum concentration of Lovastatin.  Management: Consider using a non-interacting statin (pravastatin) in patients on amiodarone. If combined, limit the lovastatin dose to 40 mg daily and monitor for evidence of lovastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Amiodarone may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Amiodarone. Management: Canadian labeling recommends avoiding this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: Amiodarone may enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: Amiodarone may increase the serum concentration of Red Yeast Rice.  Management: Consider using a non-interacting statin (pravastatin) in patients on amiodarone. If combined, limit the lovastatin dose to 40 mg daily and monitor for evidence of lovastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically, desethylamiodarone concentrations may decrease. RifAMPin may decrease the serum concentration of Amiodarone. Management: Seek alternatives.  When used together, monitor closely for decreased amiodarone concentrations/effects.  Dose adjustment may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Amiodarone. Management: Ritonavir US prescribing information lists this combination as contraindicated.  Amiodarone use should be avoided with lopinavir/ritonavir, but if the combination must be used, monitor closely for increased amiodarone serum concentrations and effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May enhance the QTc-prolonging effect of Amiodarone. Saquinavir may increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Amiodarone may increase the serum concentration of Simvastatin.  Management: Consider using a non-interacting statin (pravastatin) in patients on amiodarone. If combined, limit the simvastatin dose to 20 mg daily and monitor for evidence of simvastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Amiodarone may diminish the therapeutic effect of Sodium Iodide I131. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sofosbuvir: May enhance the bradycardic effect of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: CYP2A6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May enhance the adverse/toxic effect of Amiodarone. Telaprevir may increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Amiodarone may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: Amiodarone may increase the serum concentration of TiZANidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists.  Management: Monitor patients extra closely for evidence of increased anticoagulant effects if amiodarone is started.  Consider empiric reduction of 30% to 50% in warfarin dose, though no specific guidelines on dose adjustment have been published.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133624\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food increases the rate and extent of absorption of amiodarone. Grapefruit juice increases bioavailability of oral amiodarone by 50% and decreases the conversion of amiodarone to N-DEA (active metabolite); altered effects are possible. Management: Take consistently with regard to meals; grapefruit juice should be avoided during therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133610\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Amiodarone crosses the placenta (~10% to 50%) and may cause fetal harm when administered to a pregnant woman. Reported risks include neonatal bradycardia, QT prolongation, and periodic ventricular extrasystoles; neonatal hypothyroidism (with or without goiter); neonatal hyperthyroxinemia;  neurodevelopmental abnormalities independent of thyroid function; jerk nystagmus with synchronous head titubation; fetal growth retardation; and/or premature birth. Oral or IV amiodarone should be used in pregnant women only to treat arrhythmias refractory to other treatments or when other treatments are contraindicated (Page [ACC/AHA/HRS 2015]; Regitz-Zagrosek [ESG/AEPC/DGesGM/ESC] 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050960\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate and rhythm, blood pressure, ECG, chest x-ray, pulmonary function tests, thyroid function tests; serum glucose, electrolytes (especially potassium and magnesium), triglycerides, liver enzymes; ophthalmologic exams including fundoscopy and slit-lamp examinations, physical signs and symptoms of thyroid dysfunction (lethargy, edema of hands and feet, weight gain or loss), and pulmonary toxicity (dyspnea, cough; oxygen saturation, blood gases). Monitor pacing or defibrillation thresholds in patients with implantable cardiac devices (eg, pacemakers, defibrillators) at initiation of therapy and periodically during treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050964\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: Chronic oral dosing: 1 to 2.5 mg/L (SI: 2 to 4 micromoles/L) (parent); desethyl metabolite (active) is present in equal concentration to parent drug; serum concentrations may not be of great value for predicting toxicity and efficacy; toxicity may occur even at therapeutic concentrations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133584\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Class III antiarrhythmic agent which inhibits adrenergic stimulation (alpha- and beta-blocking properties), affects sodium, potassium, and calcium channels, prolongs the action potential and refractory period in myocardial tissue; decreases AV conduction and sinus node function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133606\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: 2 days to 3 weeks; IV: (electrophysiologic effects) within hours; Antiarrhythmic effects: 2 to 3 days to 1 to 3 weeks; mean onset of effect may be shorter in children vs adults and in patients receiving IV loading doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 1 week to 5 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration after discontinuing therapy: Variable, 2 weeks to months: Children: less than a few weeks; Adults: Several months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Duration after discontinuation may be shorter in children than adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Slow and variable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Rapid redistribution with a decrease to 10% of peak values within 30 to 45 minutes after completion of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV single dose: V<sub>dss</sub>: Mean range: 40 to 84 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: V<sub>d</sub>: 66 L/kg (range: 18 to 148 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;96%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2C8 and 3A4 to active N-desethylamiodarone metabolite; possible enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: ~50% (range: 35% to 65%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: <b>Note:</b> Half-life is shortened in children vs adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Amiodarone:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single dose: 58 days (range: 15 to 142 days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral chronic therapy: Mean range: 40 to 55 days (range: 26 to 107 days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV single dose: Mean range: 9 to 36 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">N-desethylamiodarone (active metabolite):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single dose: 36 days (range: 14 to 75 days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral chronic therapy: 61 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV single dose: Mean range: 9 to 30 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: 3 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces; urine (&lt;1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133605\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>5 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 5 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus adjusted to a pH between 6-7 using a sodium bicarbonate solution (5 g/100 mL of distilled water). Crush five 200 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light.&rdquo; Stable for 42 days at room temperature or 91 days refrigerated (preferred) (Nahata 1999; Nahata 2014).</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, Hipple TF. Stability of amiodarone in extemporaneous oral suspensions prepared from commercially available vehicles. <i>Journal</i><i>of Pediatric Pharmacy Practice</i>. 1999;4(4):186-189.</div>\r\n\n    <div class=\"reference\">Nahata MC and Pai VB. <i>Pediatric Drug Formulations.</i> 6th ed. Cincinnati, OH: Harvey Whitney Books Co; 2014.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133609\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amiodarone HCl in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/100 mL 5% (100 mL): $13.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450MG/250ML 5% (250 mL): $17.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/500ML 5% (500 mL): $22.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900MG/500ML 5% (500 mL): $44.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000MG/500ML 5% (500 mL): $24.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amiodarone HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/3 mL (3 mL): $1.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg/9 mL (9 mL): $5.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/18 mL (18 mL): $17.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nexterone Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150MG/100ML 4.21% (100 mL): $41.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360MG/200ML 4.14% (200 mL): $55.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amiodarone HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $222.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $199.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $158.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pacerone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $501.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (90): $654.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $448.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869363\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acetal (PY);</li>\n      <li>Advarone (JO);</li>\n      <li>Aldarin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Aldarone (TH);</li>\n      <li>Amidaron (UA);</li>\n      <li>Amidron (BD);</li>\n      <li>Amidrone (JO);</li>\n      <li>Amio (PH);</li>\n      <li>Amiocar (AR);</li>\n      <li>Amiodacore (IL);</li>\n      <li>Amiodarex (DE);</li>\n      <li>Amiodarona (CL);</li>\n      <li>Amiodon (LK);</li>\n      <li>Amiohexal (DE);</li>\n      <li>Amiorit (CO);</li>\n      <li>Amiron (KR, PH);</li>\n      <li>Amirone (AE, ET, QA, SA);</li>\n      <li>Ancaron (JP);</li>\n      <li>Angiodarona (BR);</li>\n      <li>Angoron (GR);</li>\n      <li>Anoion (PH);</li>\n      <li>Aratac (AU, NZ, SG, TW);</li>\n      <li>Arytmil (UA);</li>\n      <li>Atlansil (AR, BR, CL, CR, DO, GT, HN, NI, PA, PE, SV, UY);</li>\n      <li>Azoran (ID);</li>\n      <li>Braxan (MX);</li>\n      <li>Cardilor (MT, MY, TH);</li>\n      <li>Cardinorm (AU);</li>\n      <li>Cardiron (BD);</li>\n      <li>Coedarone (MX);</li>\n      <li>Corbionax (FR);</li>\n      <li>Cordan (DK, SY);</li>\n      <li>Cordarex (DE);</li>\n      <li>Cordarone (AE, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CO, CR, CU, CY, CZ, DO, EC, EE, EG, ET, FI, FR, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, VN, YE, ZM, ZW);</li>\n      <li>Cordarone X (AU, GB, IE, IN, NZ, ZA);</li>\n      <li>Cordasol (LK);</li>\n      <li>Coronovo (AR);</li>\n      <li>Darfin (MX);</li>\n      <li>Daronal (CO);</li>\n      <li>Diarona (UY);</li>\n      <li>Escodaron (CH);</li>\n      <li>Eurythmic (IN);</li>\n      <li>Forken (MX);</li>\n      <li>Hexarone (ZA);</li>\n      <li>Kendaron (ID);</li>\n      <li>Keritmon (MX);</li>\n      <li>Kordaron (UA);</li>\n      <li>Lamda (ID);</li>\n      <li>Medodarone (PH);</li>\n      <li>Myodial (PH);</li>\n      <li>Nostamin (PE);</li>\n      <li>Pacet (BD);</li>\n      <li>Prinox (PY);</li>\n      <li>Procor (IL);</li>\n      <li>Rexidron (ID);</li>\n      <li>Rithmik (AU);</li>\n      <li>Rythma (PH);</li>\n      <li>Sedacoron (AT, HK, JO, LB, QA, SA, TW, VN);</li>\n      <li>Tachydaron (DE);</li>\n      <li>Tiaryt (ID);</li>\n      <li>Trangorex (ES, VE);</li>\n      <li>Zydarone (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo; <i>Circulation</i>, 2003, 108(15):1871-909.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/14557344/pubmed\" target=\"_blank\" id=\"14557344\">14557344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bucknall CA, Keeton BR, Curry PV, et al, &quot;Intravenous and Oral Amiodarone for Arrhythmias in Children,&quot; <i>Br Heart J</i>, 1986, 56(3):278-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/3756044/pubmed\" target=\"_blank\" id=\"3756044\">3756044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalmers JR, Bobek MB, and Militello MA, &quot;Visual Compatibility of Amiodarone Hydrochloride Injection With Various Intravenous Drugs,&quot; <i>Am J Health Syst Pharm</i>, 2001, 58(6):504-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/11286148/pubmed\" target=\"_blank\" id=\"11286148\">11286148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coumel P and Fidelle J, &quot;Amiodarone in the Treatment of Cardiac Arrhythmias in Children: One Hundred Thirty-Five Cases,&quot; <i>Am Heart J</i>, 1980, 100(6 Pt 2):1063-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/7446409/pubmed\" target=\"_blank\" id=\"7446409\">7446409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coumel P, Lucet V, Do Ngoc D. The use of amiodarone in children. <i>Pacing Clin Electrophysiol</i>. 1983;6(5 Pt 1):930-939.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/6195613/pubmed\" target=\"_blank\" id=\"6195613\">6195613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Sanoski CA, Wiggins BS, et al, &ldquo;Pharmacotherapy Considerations in Advanced Cardiac Life Support,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(12):1703-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/17125434/pubmed\" target=\"_blank\" id=\"17125434\">17125434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Caen AR, Berg MD, Chameides L, et al. Part 12: pediatric advanced life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18 Suppl 2):S526-542.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/26473000 /pubmed\" target=\"_blank\" id=\"26473000 \">26473000 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Etheridge SP, Craig JE, and Compton SJ, &ldquo;Amiodarone is Safe and Highly Effective Therapy for Supraventricular Tachycardia in Infants,&rdquo; <i>Am Heart J</i>, 2001, 141(1):105-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/11136494/pubmed\" target=\"_blank\" id=\"11136494\">11136494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), et al, &quot;ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy: The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC),&quot; <i>Eur Heart J</i>, 2011, 32(24):3147-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Figa FH, Gow RM, Hamilton RM, et al, &ldquo;Clinical Efficacy and Safety of Intravenous Amiodarone in Infants and Children,&rdquo; <i>Am J Cardiol</i>, 1994, 74(6):573-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/8074040/pubmed\" target=\"_blank\" id=\"8074040\">8074040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fishberger SB, Hannan RL, Welch EM, et al, &quot;Amiodarone for Pediatric Resuscitation: A Word of Caution,&quot; <i>Pediatr Cardiol</i>, 2009, 30(7):1006-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/19495851/pubmed\" target=\"_blank\" id=\"19495851\">19495851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuster V, Ryd&eacute;n LE, Cannom DS, et al, &quot;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),&quot; <i>J Am Coll Cardiol</i>, 2006, 48(4):854-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/16904574/pubmed\" target=\"_blank\" id=\"16904574\">16904574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haas NA and Camphausen CK, &quot;Impact of Early and Standardized Treatment With Amiodarone on Therapeutic Success and Outcome in Pediatric Patients With Postoperative Tachyarrhythmia,&quot; <i>J Thorac Cardiovasc Surg</i>, 2008, 136(5):1215-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/19026806/pubmed\" target=\"_blank\" id=\"19026806\">19026806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall CM and McCormick KP, &quot;Amiodarone and Breast Feeding,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2003, 88(3):F255-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/12719404/pubmed\" target=\"_blank\" id=\"12719404\">12719404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazinski MF, Shuster M, Donnino MW, et al.<i> 2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers</i>. South Deerfield, MA: American Heart Association; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovacikova L, Hakacova N, Dobos D, et al, &quot;Amiodarone as a First-Line Therapy for Postoperative Junctional Ectopic Tachycardia,&quot; <i>Ann Thorac Surg</i>, 2009, 88(2):616-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/19632422/pubmed\" target=\"_blank\" id=\"19632422\">19632422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lane RD, Nguyen KT, Niemann JT, et al, &quot;Amiodarone for the Emergency Care of Children,&quot; <i>Pediatr Emerg Care</i>, 2010, 26(5):382-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/20453797/pubmed\" target=\"_blank\" id=\"20453797\">20453797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(suppl 2):S444-S464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/26472995/pubmed\" target=\"_blank\" id=\"26472995\">26472995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/20213839/pubmed\" target=\"_blank\" id=\"20213839\">20213839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paul T and Guccione P, &quot;New Antiarrhythmic Drugs in Pediatric Use: Amiodarone,&quot; <i>Pediatr Cardiol</i>, 1994, 15(3):132-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/8047495/pubmed\" target=\"_blank\" id=\"8047495\">8047495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry JC, Fenrich AL, Hulse JE, et al, &ldquo;Pediatric Use of Intravenous Amiodarone: Efficacy and Safety in Critically Ill Patients From a Multicenter Protocol,&rdquo; <i>J Am Coll Cardiol</i>, 1996, 27(5):1246-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/8609351/pubmed\" target=\"_blank\" id=\"8609351\">8609351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raja P, Hawker RE, Chaikitpinyo A, et al, &ldquo;Amiodarone Management of Junctional Ectopic Tachycardia After Cardiac Surgery in Children,&rdquo; <i>Br Heart J</i>, 1994, 72(3):261-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/ 7946778 /pubmed\" target=\"_blank\" id=\" 7946778 \"> 7946778 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roy D, Talajic M, Dorian P, et al, &quot;Amiodarone to Prevent Recurrence of Atrial Fibrillation. Canadian Trial of Atrial Fibrillation Investigators,&quot; <i>N Engl J Med</i>, 2000, 342(13):913-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/10738049/pubmed\" target=\"_blank\" id=\"10738049\">10738049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skrifvars MB, Kuisma M, Boyd J, et al, &quot;The Use of Undiluted Amiodarone in the Management of Out-of-Hospital Cardiac Arrest,&quot; <i>Acta Anaesthesiol Scand</i>, 2004, 48(5):582-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/15101852/pubmed\" target=\"_blank\" id=\"15101852\">15101852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soult JA, Munoz M, Lopez JD, et al, &ldquo;Efficacy and Safety of Intravenous Amiodarone for Short-Term Treatment of Paroxysmal Supraventricular Tachycardia in Children,&rdquo; <i>Pediatr Cardiol</i>, 1995, 16(1):16-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/7753695 /pubmed\" target=\"_blank\" id=\"7753695 \">7753695 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vorperian VR, Havighurst TC, Miller S, et al, &quot;Adverse Effects of Low Dose Amiodarone: A Meta-analysis,&quot; <i>J Am Coll Cardiol</i>, 1997, 30(3):791-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/9283542/pubmed\" target=\"_blank\" id=\"9283542\">9283542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimetbaum P, &quot;Amiodarone for Atrial Fibrillation,&quot; <i>N Engl J Med</i>, 2007, 356(9):935-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amiodarone-pediatric-drug-information/abstract-text/17329700/pubmed\" target=\"_blank\" id=\"17329700\">17329700</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12587 Version 239.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708616\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F133629\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F133630\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050961\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431485\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050953\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133598\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F133581\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26978976\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874279\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050966\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471287\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F133622\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050965\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F133691\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F133688\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133607\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133585\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F133676\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133590\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F133624\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133610\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050960\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1050964\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133584\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F133606\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F133605\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133609\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869363\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12587|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">Amiodarone: Drug information</a></li><li><a href=\"topic.htm?path=amiodarone-patient-drug-information\" class=\"drug drug_patient\">Amiodarone: Patient drug information</a></li></ul></div></div>","javascript":null}